Human albumin

ApprovedSmall molecule

TTonghua Anrate Biopharmaceutical Co., Ltd.

Human albumin is one of 344 small molecule programs targeting Hypoalbuminemia. It is currently in Approved.

Indications

Total Trials

Active Trials

343

Competitors

Pipeline

Status by Indication[3][1]

Indication

HypoalbuminemiaActive, not recruiting

Systemic Inflammatory Response SyndromeActive, not recruiting

PeritonitisActive, not recruiting

SepsisActive, not recruiting

MiscarriageActive, not recruiting

Oxidative StressActive, not recruiting

EncephalopathyActive, not recruiting

Septic ShockActive, not recruiting

PreeclampsiaActive, not recruiting

Gastric CancerActive, not recruiting

HypoalbuminemiaPhase 3

Active, not recruiting

Systemic Inflammatory Response SyndromePhase 3

Active, not recruiting

PeritonitisApproved

Active, not recruiting

SepsisPhase 3

Active, not recruiting

MiscarriagePhase 3

Active, not recruiting

Oxidative StressPhase 1

Active, not recruiting

EncephalopathyApproved

Active, not recruiting

Septic ShockPhase 2

Active, not recruiting

PreeclampsiaApproved

Active, not recruiting

Gastric CancerPreclinical

Active, not recruiting

Showing 10 of 15 indications

Competition

Competitive Landscape

714 competitors in Gastric Cancer

#DrugCompanyPhaseTrials

Human albumin

TTonghua Anrate Biopharmaceutical Co., Ltd.

Approved

1 2

SHR-1210

JJiangsu HengRui Medicine Co., Ltd.

Phase 3

2 3

Gemzar

Johnson & Johnson

Preclinical

—4

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

3 5

S1,

CChinese Academy of Medical Sciences

Preclinical

17 6

PD-1 Inhibitor

Johnson & Johnson

Preclinical

3 7

Induction Phase1

Genmab

Preclinical

1 8

Glutamine

Sanofi

Preclinical

1 9

Cox-2 Inhibitor

SSeoul National University Hospital

Preclinical

1 10

CEA-Targeted CAR-T Cells

CChongqing Precision Biotech Co., Ltd

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 3Recruiting

Cirrhosis

NCT05056220

Q4 2026

Post-ApprovalNot yet recruiting

Preeclampsia

NCT06107335

Phase 3Recruiting

Heart Failure

NCT06630923

Q3 2027

N/ARecruiting

Subarachnoid Hemorrhage

NCT06548477

Clinical

Trials by Indication[1]

Peritonitis2 trials

Clinical, Inflammatory, and Economic Impact of Dextran 70 in Treating Spontaneous Bacterial Peritonitis

Terminated·UUniversity of Virginia·Phase 4·NCT00570960·8 enrolled

Albumin Administration in Patients With Cirrhosis and Infections Unrelated to Spontaneous Bacterial Peritonitis

Completed·HHospital Clinic of Barcelona·Phase 3·NCT00124228·110 enrolled

Cirrhosis2 trials

Personalized Long-term Human Albumin Treatment in Patients With Decompensated Cirrhosis and Ascites

Recruiting·AAleksander Krag·Phase 3·NCT05056220·240 enrolled

A Novel COMBinATorial Therapy With Albumin and Enoxaparin in Patients With Decompensated Cirrhosis at High-risk of Poor Outcome (COMBAT Trial).

Recruiting·EEuropean Foundation for Study of Chronic Liver Failure·Phase 2·NCT05895136·90 enrolled

Hypoalbuminemia2 trials

The Therapeutic Role of Intravenous Albumin Administration for Peptic Ulcer Bleeding Patients With Hypoalbuminemia

Completed·NNational Cheng-Kung University Hospital·Phase 4·NCT01822600·91 enrolled

A Study of Recombinant Human Albumin Injection to Treat Hypoalbuminemia in Cirrhotic Patients With Ascites

Completed·TTonghua Anrate Biopharmaceutical Co., Ltd.·Phase 3·NCT06911554·416 enrolled

Subarachnoid Hemorrhage2 trials

Treatment of Subarachnoid Hemorrhage With Human Albumin

Terminated·—·Phase 1·NCT01747408·47 enrolled

Human Albumin for Clinical Outcome in Aneurysmal Subarachnoid Hemorrhages

Recruiting·HHamad Medical Corporation·N/A·NCT06548477·84 enrolled

Septic Shock1 trial

Human Albumin Treatment in Adult Septic Shock. A Study Evaluating Immune Response and Organ Failure.

Withdrawn·AAlbimmune SL·Phase 2·NCT05645887

19 more indications

Sepsis1 trial

Feasibility of 5% Albumin Compared With Balanced Crystalloid, as Intravenous Fluid Resuscitation in Adult Patients With Sepsis, Presenting as an Emergency to Hospital

Completed·UUniversity of Edinburgh·Phase 3·NCT04540094·300 enrolled

Miscarriage1 trial

Trial of the Efficacy of Intravenous Immunoglobulin for Treating Women With Unexplained Secondary Recurrent Miscarriage

Completed·RRigshospitalet, Denmark·Phase 3·NCT00722475·82 enrolled

Encephalopathy1 trial

Albumin Infusion Effects in Mortality in Patients With Cirrhosis and Hepatic Encephalopathy

Unknown status·HHospital Universitari Vall d'Hebron Research Institute·Phase 4·NCT02401490·128 enrolled

Propofol1 trial

Agitated Saline, Albumin, or Propofol-albumin Mixture for Enhanced Contrast in TEE Examinations

Completed·UUniversity of California, San Diego·N/A·NCT02613052·17 enrolled

Infusion1 trial

Effect of Albumin Infusion on Oxidative Albumin Modification, Albumin Binding Capacity and Plasma Thiol Status

Completed·MMedical University of Graz··NCT03214796·40 enrolled

Polyneuropathy1 trial

The Impact of IVIG Treatment on Critical Illness Polyneuropathy and/or Myopathy in Patients With MOF and SIRS/Sepsis

Terminated·MMedical University of Vienna·Phase 1·NCT01867645·38 enrolled

Gastric Cancer1 trial

Human Albumin and Anastomotic Leakage After Gastric Cancer Surgery

Completed·RRuijin Hospital··NCT04490668·1,049 enrolled

Oxidative Stress1 trial

The Effect of Albumin Supplementation on the Inflammatory and Oxidative Stress Markers in Septic Patients

Unknown status·UUniversity of Pecs·Phase 1·NCT03950778·30 enrolled

Pancreaticoduodenectomy1 trial

Intravenous Human Albumin In Improving Pancreaticoduodenectomy Outcomes

Unknown status·UUniversiti Kebangsaan Malaysia Medical Centre·Phase 2·NCT04418739·122 enrolled

Preeclampsia1 trial

Effect of Albumin Versus Routine Care on Hemodynamic Response and Stability in Patients With Preeclampsia Guided by a Non-invasive Hemodynamic Monitoring System During Cesarean Delivery With Spinal Anesthesia

Not yet recruiting·TThe University of Texas Health Science Center, Houston·Phase 4·NCT06107335·62 enrolled

Tolerance1 trial

Safety and Tolerance Study of Recombinant Human Albumin Injection in Healthy Subjects.

Completed·TThe First Hospital of Jilin University·Phase 1·NCT04641364·80 enrolled

Prednisolone1 trial

Intravenous Immunoglobulin and Prednisolone for RPL After ART.

Completed·—·Phase 2·NCT04701034·80 enrolled

Ovarian Hyperstimulation Syndrome1 trial

The Effect of Human Albumin Infusion on VEGF Levels in Women at Risk for Ovarian Hyperstimulation Syndrome

Withdrawn·YYale University·N/A·NCT00617864

Heart Failure1 trial

PREVENTION OF WORSENING RENAL FUNCTION OF INTRAVENUS ALBUMIN IN HEART FAILURE PATIENTS

Recruiting·—·Phase 3·NCT06630923·250 enrolled

Phase II1 trial

Phase II/III of Recombinant Human Albumin Injection

Completed·TThe First Hospital of Jilin University·Phase 2·NCT06411743·90 enrolled

After Cardiac Surgery1 trial

Endothelial Function After Cardiac Surgery

Completed·TThe Cleveland Clinic·N/A·NCT02882074·85 enrolled

Cardiac Surgery1 trial

Influence of Albumin on Acute Renal Dysfunction Associated With Cardiac Surgery Under Extracorporeal Circulation

Unknown status·FFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau·Phase 4·NCT03373318·250 enrolled

Systemic Inflammatory Response Syndrome1 trial

Albumin Administration in Cirrhotic Patients With Bacterial Infection and a Systemic Inflammatory Response Syndrome Unrelated to Spontaneous Bacterial Peritonitis

Terminated·—·Phase 3·NCT01359813·193 enrolled

Unspecified1 trial

SUbstition of PERioperative Albumin Deficiency Disorders

Completed·TTechnical University of Munich·Phase 4·NCT03167645·600 enrolled

Sources

References

[1]
ClinicalTrials.gov — 28 trial records for Human albumin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Human albumin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Human albumin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tonghua Anrate Biopharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: TTonghua Anrate Biopharmaceutical Co., Ltd.

Human albumin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Q3 2027

Trials by Indication[1]

Peritonitis2 trials

Cirrhosis2 trials

Hypoalbuminemia2 trials

Subarachnoid Hemorrhage2 trials

Septic Shock1 trial

Sepsis1 trial

Miscarriage1 trial

Encephalopathy1 trial

Propofol1 trial

Infusion1 trial

Polyneuropathy1 trial

Gastric Cancer1 trial

Oxidative Stress1 trial

Pancreaticoduodenectomy1 trial

Preeclampsia1 trial

Tolerance1 trial

Prednisolone1 trial

Ovarian Hyperstimulation Syndrome1 trial

Heart Failure1 trial

Phase II1 trial

After Cardiac Surgery1 trial

Cardiac Surgery1 trial

Systemic Inflammatory Response Syndrome1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News